TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00698256

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vegetable oil-based spread and oat-based drink (no brand name available)
Description: spread and drink (9 g stanols/d)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vegetable oil-based spread and oat-based drink (no brand name available)
Description: Spread and drink (not containing added stanols)
Study: NCT00828698

Intervention type: OTHER
Intervention: No intervention
Study: NCT00522262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Description: Women in the exercise arm underwent a year-long exercise intervention of five days per week of 45 minutes/session of moderate-vigorous intensity aerobic exercise.
Study: NCT04433611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Description: intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy~The VAS consisted of a 10 cm line ranging from 0 to 10 (anchored by 0=no pain and 10=very severe pain). Patients were asked to mark the number that represented their perceived level of pain. Based on the VAS scores, the pain level ratings were classified as: mild (rated 1-3), moderate (4-6) or severe (7-10).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % normal saline
Description: intrauterine infusion of 0.9 % normal saline
Study: NCT04612140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: The study subjects randomized in this study arm will undergo a radiosurgery procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repeated catheter ablation
Description: The study subjects randomized in this study arm will undergo repeated catheter ablation.
Study: NCT02246166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test tablet
Description: The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
Study: NCT01879345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 - 1800 mg (Group 1)
Description: 3 tablets of BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 - 2400 mg (Group 2)
Description: 4 tablets of BIA 2-093 600 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets
Study: NCT02294786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
Study: NCT04222985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 6
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV 2 Formulation 6
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular
Study: NCT02294786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections were given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol was added to the microspheres to improve suspendability
Study: NCT03820310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous Tcm cellular immunotherapy
Description: autologous cellular immunotherapy plus traditional therapy. • cells will be infused in 3-5×109 cells/100 ml 1 month after radical resection, then cells will be infused as the same dose followed by a 1 month rest period, Each subject in experimental group will receive a total of 5 cell infusions.
Study: NCT04459260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: A standardized evidence-based treatment manual based on cognitive behavior therapy, developed specifically for targeting perfectionism (Egan et al., 2016). Includes the following components: 1) providing psychoeducation about perfectionism and creating an individualized conceptualization 2) broadening the domains for self-evaluation 3) testing out beliefs and predictions, and 4) addressing personal standards and self-criticism.~Week 1: Understanding your perfectionism.~Week 2: Your own model, values, and motivation.~Week 3: Surveys and experiments.~Week 4: Dealing with perfectionistic behaviors.~Week 5: New ways of thinking.~Week 6: Self-criticism and self-compassion.~Week 7: Self-worth.~Week 8: Maintain and continue positive change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol
Description: A standardized evidence-based treatment manual based on cognitive behavior therapy, developed to target the shared emotional factors in depression and anxiety disorders (Ellard et al., 2010). Fundamental to this approach is to register and become more aware of the emotions, cognitions, and physical sensations that occur in difficult situation, and to try out more adaptive ways of coping in these instances.~Week 1: Emotional symptoms.~Week 2: Understanding your emotions.~Week 3: Emotional awareness.~Week 4: Thoughts.~Week 5: Behaviors.~Week 6: Emotional exposure.~Week 7: Continued emotional exposure.~Week 8: Planning ahead.
Study: NCT00953498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: After randomization, patients will be treated by pioglitazone or rosiglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: treatment with rosiglitazone at a dose between 4mg and 8 mg/day
Study: NCT03332485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECP Colon Prep Kit
Description: ECP Colon Prep Kit
Study: NCT04222985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Route of administration: Intramuscular
Study: NCT01989663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% vaginally applied tenofovir gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir film- 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Film-40 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: HEC Placebo Gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Film
Study: NCT01588821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60 mg daily by mouth
Study: NCT02472093

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group did brief educational sessions.
Study: NCT02319356

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: (BRJ, containing NO3-, 6.2 mmol/day, administered as 500ml Beet it Sport Shots, James White drinks, Ipswich uk)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beetroot juice
Description: (PL, NO3-depleted beetroot juice, administered as 500ml Placebo Beet it Sport Shots, James White drinks, Ipswich uk)
Study: NCT01744561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
Study: NCT03204344

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate (Outfast)
Description: For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated by an endocrinologist according to patients' daily glucose controlling plan.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated is the same way as described above.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Routine fasting
Description: For all patients, routine fasting (water drinking allowed) begin from 22:00 on the day before surgery until entering the operating room on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added in the 5% glucose (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, and magnesium sulfate) are added when considered necessary.
Study: NCT03112811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Description: The manual technique of the chest physiotherapy to move the secretions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Description: The manual technique of the chest physiotherapy to move the secretions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation
Description: The instrumental technique of the chest physiotherapy to move the secretions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation
Description: The instrumental technique of the chest physiotherapy to move the secretions
Study: NCT03735940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spot monitoring device, excl. Sham
Description: o During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. o During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
Study: NCT03932240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate (FC)
Description: The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: The standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL.
Study: NCT02246361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Information Leaflet (PIL)
Description: Patient Information Leaflet (PIL) about infectious colitis, diverticulitis, pneumonitis, prostatitis or either pyelonephritis is given to the patient related to his disease during the consultation
Study: NCT04154098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scapula orthosis assistance
Description: Participants are elevating their arm while their scapula is assisted by the scapula orthosis
Study: NCT03332485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MoviPrep®
Description: MoviPrep®
Study: NCT01987531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: left ventricular epicardial pacing lead
Study: NCT03737851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elezanumab
Description: solution for infusion
Study: NCT04362020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distal radial access
Description: Distal radial access and No anticoagulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distal radial access
Description: Distal radial access and ACT-guided anticoagulation
Study: NCT00704821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC299
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC299
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC299
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC299
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous infusion
Study: NCT01638520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pascolizumab
Description: 0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline (volume determined based on weight of patient, and cohort of enrollment)
Study: NCT04353063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care with a personalized care
Description: During the 4-week intervention, participants will be given stickers by the research assistant to increase their motivation to walk. A sticker will be given once a participant reaches a daily walking-time goal. The number of stickers participants receive depends on the number of days they reach their daily goals. The stickers can be redeemed for the participant's choice of gift in the gift shelf of the ward or on a gift card. A final assessment will be conducted at week 4. The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4
Study: NCT01101022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPD489
Description: 1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule per day, daily throughout the double-blind treatment period (10 weeks)
Study: NCT03737851

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: solution for infusion
Study: NCT00088829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: subjects will receive paclitaxel neoadjuvantly

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: subjects will have a biopsy to collect tissue for gene microarray analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: All subjects will have a biopsy to collect tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: paclitaxel is given neoadjuvantly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: All patients will receive paclitaxel neoadjuvantly
Study: NCT00731783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Mupirocin Ointment
Description: Apply ointment to the anterior nares twice daily for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Mupirocin Ointment
Description: Apply ointment to the anterior nares twice daily for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% Chlorhexidine liquid soap
Description: Bathe with liquid soap daily for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% Chlorhexidine liquid soap
Description: Bathe with liquid soap daily for 5 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hygiene protocol
Description: Follow key hygiene tips indefinitely. Tips are:~* Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~* Use liquid(pour or pump) soaps instead of bar soaps.~* Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~* Do not share personal care items such as razors and brushes.~* Wash all sheets and towels in hot water. Wash sheets every week.~* Use towels and wash cloths only once before washing and do not share.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hygiene protocol
Description: Follow key hygiene tips indefinitely. Tips are:~* Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~* Use liquid(pour or pump) soaps instead of bar soaps.~* Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~* Do not share personal care items such as razors and brushes.~* Wash all sheets and towels in hot water. Wash sheets every week.~* Use towels and wash cloths only once before washing and do not share.
Study: NCT01138540

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lateral-Trendelenburg position
Description: lateral-Trendelenburg position of patients laying in the bed of the ICU, keeping trachea and tracheal tube horizontal, compared to the standard treatment (semirecumbent position) for the prevention of VAP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lateral-Trendelenburg position
Description: lateral-Trendelenburg position of patients laying in the bed of the ICU, keeping trachea and tracheal tube horizontal, compared to the standard treatment (semirecumbent position) for the prevention of VAP
Study: NCT02658045

Intervention type: DEVICE
Intervention: Standard Oximeter
Description: Oxygen saturation will be measured by standard oximeter

Intervention type: DEVICE
Intervention: Standard Oximeter
Description: Oxygen saturation will be measured by standard oximeter

Intervention type: DEVICE
Intervention: Oxitone oximeter
Description: Oxygen saturation will be measured by Oxitone oximeter

Intervention type: DEVICE
Intervention: Oxitone oximeter
Description: Oxygen saturation will be measured by Oxitone oximeter
Study: NCT03281460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation
Description: laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic myomectomy or hysterectomy without any morcellation bag
Description: laparoscopic myomectomy or hysterectomy without any morcellation bag
Study: NCT03620175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TolaSure Topical Gel
Description: TolaSure topical gel is applied to skin punch biopsies daily over the course of 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TolaSure Topical Gel
Description: TolaSure topical gel is applied to skin punch biopsies daily over the course of 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TolaSure Topical Gel
Description: TolaSure topical gel is applied to skin punch biopsies daily over the course of 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TolaSure Topical Gel
Description: TolaSure topical gel is applied to skin punch biopsies daily over the course of 2 weeks.